SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:gup.ub.gu.se/176782"
 

Sökning: id:"swepub:oai:gup.ub.gu.se/176782" > Insulin Pump-Long-T...

Insulin Pump-Long-Term Effects on Glycemic Control: An Observational Study at 10 Diabetes Clinics in Sweden

Carlsson, Britt-Marie (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
Attvall, Stig, 1950 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
Clements, M. (författare)
visa fler...
Gumpeny, S. R. (författare)
Pivodic, A. (författare)
Sternemalm, L. (författare)
Lind, Marcus, 1976 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
visa färre...
 (creator_code:org_t)
Mary Ann Liebert Inc, 2013
2013
Engelska.
Ingår i: Diabetes Technology & Therapeutics. - : Mary Ann Liebert Inc. - 1520-9156 .- 1557-8593. ; 15:4, s. 302-307
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Aim: This study examined long-term effects of continuous subcutaneous insulin infusion (CSII) in clinical practice on glycemic control in patients with type 1 diabetes. Subjects and Methods: We evaluated all type 1 diabetes patients at 10 diabetes outpatient clinics in Sweden who had been treated with CSII for at least 5.5 years and had valid glycated hemoglobin (HbA1c) data before starting pump use and at 5 years±6 months. Controls treated with multiple daily insulin injections (MDI) over a time-matched period were also evaluated. Results: There were 331 patients treated with CSII at least 5.5 years at the 10 clinics. Of these, 272 (82%) fulfilled the inclusion criteria. Patients treated with CSII were younger than those treated with MDI (mean age, 38.6 vs. 45.6 years; P<0.001), more were women (56% vs. 43%; P<0.001), and diabetes duration was shorter (mean, 15.1 years vs. 20.1 years; P<0.001). After adjusting for variables differing at baseline and influencing the change in HbA1c over the study period, the reduction in HbA1c remained statistically significant at 5 years and was estimated to be 0.20% (95% confidence interval [CI] 0.07–0.32) (2.17mmol/mol [95% CI 0.81–3.53]) (P=0.002). The corresponding adjusted reduction at years 1 and 2 was 0.42% (95% CI 0.31–0.53) (4.59mmol/mol [95% CI 3.41–5.77]) (P<0.001) and 0.43% (95% CI 0.31–0.55) (4.71mmol/mol [95% CI 3.38–6.04]) (P<0.001), respectively. The effect of insulin pump use versus controls on HbA1c decreased significantly with time (P<0.001). Conclusions: Use of CSII in clinical practice in Sweden is associated with an approximately 0.2% (2mmol/mol) reduction in HbA1c after 5 years.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Annan medicin och hälsovetenskap (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Other Medical and Health Sciences (hsv//eng)

Nyckelord

quality-of-life
type-1
infusion
complications
hypoglycemia
injections
glargine
mellitus
therapy

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy